Reuters | Dec 28, 2020 16:15
By Francesco Guarascio
BRUSSELS (Reuters) - The distribution of an initial 200 million doses of the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech across the European Union will be completed by September, a spokesman for the EU Commission said on Monday.
The protracted timetable, which was previously unknown, confirms that the bloc, with a population of 450 million, will need vaccines from other suppliers to speed up inoculations against the coronavirus.
Most EU countries began inoculating healthcare workers and vulnerable people on Sunday with the Pfizer vaccine, which is the only one so far authorised in the 27-nation bloc, and requires a two-dose regimen.
"Distribution of the full 200 million doses is scheduled to be completed by September 2021," the spokesman told Reuters in an emailed statement.
A spokesman for Pfizer declined to comment on specific schedules or whether the timeline indicated by the Commission represented a delay in planned supplies, adding: "Our timelines are aspirational and can shift based on capacity and manufacturing timelines. These considerations will in turn refine supply projections and delivery schedules".
Talks are underway on delivery of a further 100 million doses which are optional under the contract sealed with the two companies, the EU spokesman said, confirming an earlier report from Reuters.
The timetable for the additional doses is unclear.
Pfizer's spokesman said the option for another 100 million doses had not been concluded.
The EU spokesman said most supply contracts agreed by the EU with COVID-19 vaccine makers foresee the majority of deliveries completed by the end of next year.
The EU has signed advance purchase agreements with Pfizer-BioNTech, AstraZeneca, Johnson & Johnson (NYSE:JNJ), Moderna (NASDAQ:MRNA), Sanofi (PA:SASY) and CureVac for a total of nearly 2 billion doses.
The bloc's drug regulator is to decide on the possible approval of the Moderna vaccine on Jan. 6, and has said that it could receive applications for approval from AstraZeneca and Johnson & Johnson in the first quarter of next year.
The EU Commission spokesman added that under some of the agreed contracts, first deliveries could start by March.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Get free real time quotes, charts and alerts on stocks, indices, currencies, commodities and bonds. Get free top of the line technical analysis/predictors.
More content, faster quotes and charts, and a smoother experience is available only on the App.